1
|
Hasnat MA, Cheang I, Dankers W, Lee JPW, Truong LM, Pervin M, Jones SA, Morand EF, Ooi JD, Harris J. Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammation. Immunol Cell Biol 2022; 100:605-623. [PMID: 35652357 PMCID: PMC9542007 DOI: 10.1111/imcb.12562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 05/08/2022] [Accepted: 05/30/2022] [Indexed: 11/26/2022]
Abstract
Studies have highlighted a critical role for autophagy in the regulation of multiple cytokines. Autophagy inhibits the release of interleukin (IL)‐1 family cytokines, including IL‐1α, IL‐1β and IL‐18, by myeloid cells. This, in turn, impacts the release of other cytokines by myeloid cells, as well as other cells of the immune system, including IL‐22, IL‐23, IL‐17 and interferon‐γ. Here, we assessed the impact of genetic depletion of the autophagy gene Atg7 in myeloid cells on acute and chronic inflammation. In a model of acute lipopolysaccharide‐induced endotoxemia, loss of autophagy in myeloid cells resulted in increased release of proinflammatory cytokines, both locally and systemically. By contrast, loss of Atg7 in myeloid cells in the Lyn−/− model of lupus‐like autoimmunity resulted in reduced systemic release of IL‐6 and IL‐10, with no effects on other cytokines observed. In addition, Lyn−/− mice with autophagy‐deficient myeloid cells showed reduced expression of autoantibodies relevant to systemic lupus erythematosus, including anti‐histone and anti‐Smith protein. In vitro, loss of autophagy, through pharmacological inhibition or small interfering RNA against Becn1, inhibited IL‐10 release by human and mouse myeloid cells. This effect was evident at the level of Il10 messenger RNA expression. Our data highlight potentially important differences in the role of myeloid cell autophagy in acute and chronic inflammation and demonstrate a direct role for autophagy in the production and release of IL‐10 by macrophages.
Collapse
Affiliation(s)
- Md Abul Hasnat
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - IanIan Cheang
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Wendy Dankers
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Jacinta PW Lee
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Lynda M Truong
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Mehnaz Pervin
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Sarah A Jones
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Eric F Morand
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - Joshua D Ooi
- Regulatory T Cell Therapies Group, Centre for Inflammatory Diseases Department of Medicine, School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| | - James Harris
- Centre for Inflammatory Diseases, Department of Medicine School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton VIC Australia
| |
Collapse
|
2
|
Chen XY, Sun RX, Zhang WY, Liu T, Zheng YH, Wu Y. [Molecular mechanisms and relationship of M2-polarized macrophages with early response in multiple myeloma]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 38:480-486. [PMID: 28655090 PMCID: PMC7342963 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
目的 探讨替代活化型巨噬细胞(M2 MΦ)和多发性骨髓瘤(MM)早期治疗反应的关系及其在发病机制中的可能作用。 方法 采用免疫组化法标记240例MM患者骨髓标本中的MΦ;建立体外M2 MΦ诱导培养体系,构建Transwell共培养模型与RPMI 8226和U266细胞共培养,CCK-8法检测M2 MΦ对细胞增殖的影响,流式细胞术检测对地塞米松(1 µ mol/L)诱导骨髓瘤细胞凋亡的影响,ELISA法检测对TNF-α和IL-6表达的影响,real time PCR法检测对趋化因子、血管内皮生长因子(VEGF)及其受体表达的影响。 结果 ①依据骨髓组织M2 MΦ浸润程度将患者分为高浸润组(92例)和低浸润组(148例),高浸润组患者早期治疗有效率明显低于低浸润组,差异有统计学意义(23.9%对73.0%,χ2=60.31,P<0.001)。②培养24、36 h,共培养组细胞增殖能力较对照组显著上升:M2 MΦ+RPMI 8226细胞组与对照组比较,P值分别为0.005、0.020;M2 MΦ+U266细胞与对照组比较,P值分别为0.030、0.020。③地塞米松诱导后,共培养组与对照组比较,RPMI 8226细胞凋亡率下降(29.0%对71.0%,t=4.97,P=0.008),U266细胞凋亡率也下降(24.9%对67.7%,t=6.99,P=0.002)。④共培养48 h后,与对照组比较,加入M2 MΦ后可促进RPMI 8226和U266细胞分泌IL-6、TNF-α,促进表达CCL2、CCL3、CCR2、CCR5、VEGFA、VEGFR-1和VEGFR-2。 结论 MM患者骨髓组织M2 MΦ浸润程度和早期治疗反应相关。M2 MΦ通过促进骨髓瘤细胞分泌系列炎症因子、趋化因子和相关受体的表达,从而促进骨髓瘤细胞增殖以及保护骨髓瘤细胞免于凋亡。
Collapse
Affiliation(s)
- X Y Chen
- Department of Hematology and Research Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China
| | | | | | | | | | | |
Collapse
|
3
|
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators Inflamm 2017; 2017:1852517. [PMID: 29089667 PMCID: PMC5635476 DOI: 10.1155/2017/1852517] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Accepted: 09/11/2017] [Indexed: 12/23/2022] Open
Abstract
Multiple myeloma (MM) is typically exemplified by a desynchronized cytokine system with increased levels of inflammatory cytokines. We focused on the contrast between inflammatory and anti-inflammatory systems by assessing the role of cytokines and their influence on MM. The aim of this review is to summarize the available information to date concerning this equilibrium to provide an overview of the research exploring the roles of serum cytokines in MM. However, the association between MM and inflammatory cytokines appears to be inadequate, and other functions, such as pro-proliferative or antiproliferative effects, can assume the role of cytokines in the genesis and progression of MM. It is possible that inflammation, when guided by cancer-specific Th1 cells, may inhibit tumour onset and progression. In a Th1 microenvironment, proinflammatory cytokines (e.g., IL-6 and IL-1) may contribute to tumour eradication by attracting leucocytes from the circulation and by increasing CD4 + T cell activity. Hence, caution should be used when considering therapies that target factors with pro- or anti-inflammatory activity. Drugs that may reduce the tumour-suppressive Th1-driven inflammatory immune response should be avoided. A better understanding of the relationship between inflammation and myeloma will ensure more effective therapeutic interventions.
Collapse
|
4
|
Revez JA, Matheson MC, Hui J, Baltic S, James A, Upham JW, Dharmage S, Thompson PJ, Martin NG, Hopper JL, Ferreira MAR. Identification of STOML2 as a putative novel asthma risk gene associated with IL6R. Allergy 2016; 71:1020-30. [PMID: 26932604 DOI: 10.1111/all.12869] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/25/2016] [Indexed: 01/05/2023]
Abstract
BACKGROUND Functional variants in the interleukin-6 receptor gene (IL6R) are associated with asthma risk. We hypothesized that genes co-expressed with IL6R might also be regulated by genetic polymorphisms that are associated with asthma risk. The aim of this study was to identify such genes. METHODS To identify genes whose expression was correlated with that of IL6R, we analyzed gene expression levels generated for 373 human lymphoblastoid cell lines by the Geuvadis consortium and for 38 hematopoietic cell types by the Differentiation Map Portal (DMAP) project. Genes correlated with IL6R were then screened for nearby single nucleotide polymorphisms (SNPs) that were significantly associated with both variation in gene expression levels (eSNPs) and asthma risk. RESULTS We identified 90 genes with expression levels correlated with those of IL6R and that also had a nearby eSNP associated with disease risk in a published asthma GWAS (N = 20 776). For 16 (18%) genes, the association between the eSNP and asthma risk replicated with the same direction of effect in a further independent published asthma GWAS (N = 27 378). Among the top replicated associations (FDR < 0.05) were eSNPs for four known (IL18R1, IL18RAP, BCL6, and STAT6) and one putative novel asthma risk gene, stomatin-like protein 2 (STOML2). The expression of STOML2 was negatively correlated with IL6R, while eSNPs that increased the expression of STOML2 were associated with an increased asthma risk. CONCLUSION The expression of STOML2, a gene that plays a key role in mitochondrial function and T-cell activation, is associated with both IL-6 signaling and asthma risk.
Collapse
Affiliation(s)
- J. A. Revez
- QIMR Berghofer Medical Research Institute; Brisbane Qld Australia
| | - M. C. Matheson
- Melbourne School of Population and Global Health; The University of Melbourne; Melbourne Vic. Australia
| | - J. Hui
- PathWest Laboratory Medicine of Western Australia (WA); Nedlands WA Australia
- School of Population Health; The University of WA; Nedlands WA Australia
- School of Pathology and Laboratory Medicine; The University of WA; Nedlands WA Australia
- Busselton Population Medical Research Institute; Sir Charles Gairdner Hospital; Perth WA Australia
| | - S. Baltic
- Institute for Respiratory Health; University of WA; Perth WA Australia
| | - A. James
- Busselton Population Medical Research Institute; Sir Charles Gairdner Hospital; Perth WA Australia
- School of Medicine and Pharmacology; University of Western Australia; Nedlands WA Australia
- Department of Pulmonary Physiology; West Australian Sleep Disorders Research Institute; Nedlands WA Australia
| | - J. W. Upham
- School of Medicine; Translational Research Institute; The University of Queensland; Brisbane Qld Australia
| | - S. Dharmage
- Melbourne School of Population and Global Health; The University of Melbourne; Melbourne Vic. Australia
| | - P. J. Thompson
- Institute for Respiratory Health; University of WA; Perth WA Australia
- School of Medicine and Pharmacology; University of Western Australia; Nedlands WA Australia
| | - N. G. Martin
- QIMR Berghofer Medical Research Institute; Brisbane Qld Australia
| | - J. L. Hopper
- Melbourne School of Population and Global Health; The University of Melbourne; Melbourne Vic. Australia
| | | | | |
Collapse
|
5
|
Li Y, Li N, Yan Z, Li H, Chen L, Zhang Z, Fan G, Xu K, Li Z. Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma. ACTA ACUST UNITED AC 2015; 21:144-51. [PMID: 26146985 DOI: 10.1179/1607845415y.0000000029] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
OBJECTIVE The NLRP3 inflammasome complex, an important regulatory factor of inflammation and cell apoptosis, has attracted considerable attention in the development of tumor. Here, we analyzed the expression and clinical significance of NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma (MM). METHODS Peripheral blood and bone marrow of 38 newly diagnosed myeloma patients and 25 age- and gender-matched healthy people were studied. NLRP3 and caspase-1 were analyzed using quantitative real-time polymerase chain reaction and Western blot and IL-1beta, IL-18, RANKL, and OPG were evaluated by enzyme-linked immunosorbent assay. RESULTS We showed that aberrant NLRP3 and caspase-1 expression were observed in MM and down-regulated compared with the healthy people. We further demonstrated that NLRP3 mRNA was negatively correlated with beta2-microglobulin and plasma cell percentage in MM. The downstream cytokines IL-18 and sRANKL/OPG in MM patients were higher than that in control group. Moreover, the lower mRNA levels of NLRP3 and caspase-1 were shown to be positively correlated with IL-1beta in newly diagnosed MM patients. CONCLUSIONS This study demonstrated that dysregulated expression of NLRP3-caspase-1-IL-1beta axis was observed in patients with MM, suggesting they might be involved in the pathogenesis of MM.
Collapse
Affiliation(s)
- Yanjie Li
- a Laboratory Center of Diagnostics , Xuzhou Medical College , China
| | - Ning Li
- b Department of Geratology , The Second Affiliated Hospital of Xuzhou Medical College, General Hospital of Xuzhou Mining Group , China
| | - Zhiling Yan
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| | - Hujun Li
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| | - Lili Chen
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| | - Zhiyao Zhang
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| | - Guoqin Fan
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| | - Kailin Xu
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| | - Zhenyu Li
- c Department of Hematology , The Affiliated Hospital of Xuzhou Medical College , China
| |
Collapse
|
6
|
High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity. Tumour Biol 2015; 36:8491-7. [PMID: 26026586 DOI: 10.1007/s13277-015-3586-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Accepted: 05/19/2015] [Indexed: 12/17/2022] Open
Abstract
Multiple myeloma (MM) is a plasma cell neoplasm characterized by bone marrow infiltration from malignant plasma cells. Mast cells play an important role in inflammation and angiogenesis in malignant diseases. The aim of the study was to evaluate the mast cell density in bone marrow of untreated MM patients with markers of disease activity such as serum interleukin-6 (IL-6), B2M, and C-reactive protein (CRP), the grade of bone marrow infiltration, and the levels of produced paraprotein. We studied 86 newly diagnosed MM patients (46 males, 40 females, mean age 59 ± 13.7 years). Thirty of them reached plateau phase after chemotherapy and 20 healthy volunteers. According to the criteria of International Staging System (ISS) staging system, 23 patients had stage I, 30 had stage II, and 33 had stage III. The serum concentrations of CRP, B2M, and IL-6, and the mast cell density (MCD) values were significantly higher in MM patients' group (1.6 ± 1.8, 4.3 ± 2.9, 7.1 ± 5.1, and 9 ± 4.8), in comparison with those found in control group (0.4 ± 0.1, 1.5 ± 0.6, 1.1 ± 0.5, and 1.9 ± 0.7; p < 0.001 in all the cases). Significant differences were found between the grade of infiltration in bone marrow, and the paraprotein values in patients' serum before and after chemotherapy. Furthermore, there was a significant correlation between the MCD values and the prognostic markers CRP (r = 0.452, p < 0.0001), IL-6 (r = 0.475, p < 0.0001), bone marrow infiltration (r = 0.333, p < 0.0002), and serum paraprotein levels(r = 0.221, p < 0.04). High MCD values strengthen the hypothesis that mast cells participate in the pathogenesis of disease progression and may be used as an indicator of the disease activity.
Collapse
|
7
|
Jurczyszyn A, Czepiel J, Biesiada G, Gdula-Argasińska J, Cibor D, Owczarek D, Perucki W, Skotnicki AB. HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma. J Cancer 2014; 5:518-24. [PMID: 24963356 PMCID: PMC4067511 DOI: 10.7150/jca.9266] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 05/22/2014] [Indexed: 11/05/2022] Open
Abstract
Background. In the last few years, it has been widely reported that proinflammatory and angiogenic cytokines are important for the development and progression of multiple myeloma (MM). Objectives. To further validate and acquire more insight into this view we decided to check whether plasma levels of certain cytokines and their soluble receptors differ between MM patients and healthy subjects. Patients and Methods. The study was conducted in 76 MM patients aged 22 to 77 years (60±10 years) and 35 healthy controls aged 20 to 63 years (33±10 years). Plasma levels of interleukin-6 (IL-6), b-fibroblast growth factor (b-FGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1), as well as soluble receptors for IL-6 (sIL-6R) and VEGF (sVEGF-R2) were measured using enzyme-linked immunosorbent assay (ELISA). Results. Significantly higher plasma levels of IL-6 (13.65±42.61 vs. 1.04±1.12 pg/ml, p=0.006), HGF (2174±2714 vs. 648±130 pg/ml, p<0.001), b-FGF (7.92±10.78 vs. 2.54±5.38 pg/ml, p<0.001) and sIL-6R (37.1±14.2 vs. 25.3±6.4 ng/ml, p=0.003) were observed in MM patients vs. healthy controls, respectively. Plasma sVEGF-R2 was significantly lower in MM patients than in controls (7518±2119 vs. 8725±1281 pg/ml, respectively; p<0.001). We observed an inverse correlation between length of treatment and the level of sIL-6R, and TGF-β1 in plasma. Conclusions. Plasma levels of HGF, b-FGF, IL-6 and sIL-6R in MM patients were higher when compared to the control group. Antineoplastic therapy leads to a time-dependent decrease in plasma levels of sIL-6R, and TGF-β1 in MM patients. Blood plasma level of HGF is an optimal measure to differentiate patients in whom disease is progressing versus patients who respond to therapy.
Collapse
Affiliation(s)
- Artur Jurczyszyn
- 1. Department of Haematology, University Hospital, Kraków, Poland
| | - Jacek Czepiel
- 2. Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland
| | - Grażyna Biesiada
- 2. Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland
| | - Joanna Gdula-Argasińska
- 3. Department of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Dorota Cibor
- 2. Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland
| | - Danuta Owczarek
- 2. Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland
| | - William Perucki
- 4. Students' Scientific Society, Jagiellonian University Medical College, Kraków, Poland
| | | |
Collapse
|